MEDGENE THERAPEUTICS
MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)—using NIH patented technology with Worldwide Exclusive License Agreement of commercialization.
MEDGENE THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2015-01-01
Address:
Silver Spring, Maryland, United States
Country:
United States
Status:
Active
Contact:
(301) 500-6746
Total Funding:
1.15 M USD
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Current Employees Featured
Founder
More informations about "MedGene Therapeutics"
MedGene Therapeutics - Crunchbase Company Profile & Funding
MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology. View contacts for MedGene Therapeutics to access new leads and …See details»
MedGene Therapeutics, Inc. | LinkedIn
MedGene Therapeutics, Inc. is a T cell immunotherapy company whose primary goal is the treatment of solid tumor cancers. T cells are the body’s major natural defense against the tumors..See details»
MedGene Therapeutics Company Profile 2024: Valuation, Funding ...
Developer of biotechnology company based in the USA. The company offers autologous T-cell therapies which uses innovative technology (AUTO-Tâ„¢) that allows patient anti-tumor T cells …See details»
MedGene Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
GAITHERSBURG, Md., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to …See details»
MedGene Therapeutics, Inc. - Org Chart, Teams, Culture & Jobs
MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue …See details»
MedGene Therapeutics - Funding, Financials, Valuation & Investors
MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology.See details»
MedGene Therapeutics | BioPharm America
MedGene Therapeutics, Inc. is a cell and gene therapy start-up company (late pre-clinical stage) based in Gaithersburg, MD. We use modified CD8 T cells to battle cancer, with 2 innovations …See details»
MedGene Therapeutics - Crunchbase
MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology.See details»
MedGene Therapeutics Publishes Preclinical Data Demonstrating …
Data in the paper highlight the potential of Krüppel-like factor 4 (Klf4), a naturally-occurring human transcription factor, to overcome the T cell exhaustion problem that currently limits the...See details»
MedGene Therapeutics - VentureRadar
MedGene Therapeutics is developing twin foundational technologies for cell therapy targeting solid tumors. PBL-Tâ„¢ is a version of Tumor Infiltrating Lymphocyte (TIL) therapy based on …See details»
MedGene Therapeutics - Products, Competitors, Financials, …
MedGene Therapeutics specializes in the development of immunotherapy treatments within the biotechnology sector. The company's main offerings include autologous adoptive cell therapy, …See details»
MedGene Therapeutics Publishes Preclinical Data ... - BioSpace
Nov 29, 2022 · MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to solid tumors, today announced the publication of a peer …See details»
MedGene Therapeutics Publishes Preclinical Data Demonstrating …
Nov 29, 2022 · Data in the paper highlight the potential of Krüppel-like factor 4 ( Klf4 ), a naturally-occurring human transcription factor, to overcome the T cell exhaustion problem that currently …See details»
MedGene Therapeutics - Contacts, Employees, Board Members
MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology.See details»
RCT-501 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · Understand key drug designations in just a few clicks with Synapse. RCT-501, Initially developed by MedGene Therapeutics, Inc., Now, its global highest R&D status is …See details»
MedGene Therapeutics - Tech Stack, Apps, Patents & Trademarks
MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology.See details»
Medgene Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Medgene. Use the PitchBook Platform to explore the full profile.See details»
MedGene Therapeutics Publishes Preclinical Data - GlobeNewswire
GAITHERSBURG, Md., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MedGene Therapeutics, Inc. (MedGene), a biopharmaceutical company dedicated to bringing adoptive cell therapies to …See details»
RCT-701 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · Understand key drug designations in just a few clicks with Synapse. RCT-701, Initially developed by MedGene Therapeutics, Inc., Now, its global highest R&D status is …See details»